• About
  • Overview
  • Management
    • Dr. Joe Lewis
    • Dr. Bernd Janssen
    • Dr Fiona McLaughlin
    • Sally-Anne Watson
  • Supervisory Board
  • Scientific Advisory Board
  • Investors
• Programs
  • Mechanism of Action
  • Technology
  • Products
  • Technology Fact Sheet
• News
  • Latest News
  • Upcoming Events
  • Download Area
• Careers
  • Vacancies
• Contact
  • Contact
• Home
  • Home

Welcome to Elara Pharmaceuticals

ELARA Pharmaceuticals GmbH is a pre-clinical stage biopharmaceutical company founded in 2006 as a spin-out of the European Molecular Biology Laboratory (EMBL) in Heidelberg.

The company focuses on the development of novel treatments for malignant diseases through inhibition of the hypoxia signaling pathway (HIF), which is crucial for tumor survival and growth, and through induction of apoptosis. Since HIF is upstream of validated oncology targets, this approach is expected to yield drugs of superior efficacy to current standards of care.

ELARA presented poster at AACR.

ELARA Pharmaceuticals presented a poster (LB-385) on 5th April at AACR American Association for Cancer Research, Orlando on the preclinical development of EL102 and data on its use in prostate cancer and multiple myeloma.

Download poster (pdf)